share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $5 Price Target

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $5 Price Target

Benchmark将Emergent BioSolutions上调至收购,宣布
Moomoo 24/7 ·  03/07 10:39

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $5 price target.

基准分析师罗伯特·瓦瑟曼将Emergent BioSolutions(纽约证券交易所代码:EBS)从 “持有” 上调至 “买入”,并宣布了5美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发